Calls for medicinal cannabis to be legalised to help people now turning to the streets for their pain relief
He's been threatened, his home has been attacked, and he lives in fear of going to jail for possession of cannabis.
But he says he has no choice.
He suffers from ME, or Chronic Fatigue Syndrome, and he spoke exclusively with ITV News Central to describe how being denied legal cannabis-based medication has meant he is forced to turn to the streets for his pain relief.
It comes as the government's Crime Prevention Minister called for medicinal cannabis to be legalised - telling ITV News Central he believes it is wrong to deny people a product which could help.
See the full report from Charlotte Cross here:
Home Officer Minister Norman Baker told ITV News Central that he had spoken to people suffering from conditions including cancer, epilepsy, and multiple sclerosis who all said they used cannabis as they could not find any other medication which worked.
He said he had written to the Department of Health to ask them to consider the issue, and wanted a cross-party review into
The ME patient, who struggles to walk much of the time, told ITV News Central he has repeatedly tried - and failed - to get his local NHS trust to pay for Sativex, which is the government's first legal, licensed cannabis-based medication.
So now, he said, he regularly has to trawl the back streets of Birmingham and deal with violent crooks to get something which helps.
While Sativex is usually prescribed for people with multiple sclerosis, health bosses have said it can be used for other conditions including ME - but only if local NHS trusts decide to fund it.
A spokesman for Birmingham CrossCity Clinical Commissioning Group said they could not comment specifically on individual cases, but added:
A Home Office spokeswoman said there were "no plans" to review how cannabis is classified.
And a spokeswoman for the MHRA - the body responsible for licensing new medicines - said they could not confirm or deny whether there were any other applications in place for cannabis-based medication due to "commercial sensitivity".